Australia - Inggris - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone furoate, quantity: 200 microgram; vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram) - inhalation, powder for - excipient ingredients: magnesium stearate; lactose monohydrate - asthma,breo ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,vilanterol, an active ingredient in breo ellipta, is a long-acting beta-2-agonist (laba). a class effect of all labas can be an increased risk of asthma death (see precautions).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); umeclidinium bromide, quantity: 74.2 microgram (equivalent: umeclidinium, qty 62.5 microgram); fluticasone furoate, quantity: 100 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - asthma,trelegy ellipta is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta2-agonist.,copd,trelegy ellipta is indicated for the maintenance treatment of adults with moderate to severe copd who require treatment with lama+laba+ics.,trelegy ellipta is not indicated for the initiation of therapy in copd.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); umeclidinium bromide, quantity: 74.2 microgram (equivalent: umeclidinium, qty 62.5 microgram); fluticasone furoate, quantity: 200 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - asthma,trelegy ellipta is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta2-agonist.,copd,trelegy ellipta is indicated for the maintenance treatment of adults with moderate to severe copd who require treatment with lama+laba+ics.,trelegy ellipta is not indicated for the initiation of therapy in copd.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] . therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, s

Amerika Serikat - Inggris - NLM (National Library of Medicine)

rebel distributors corp - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol xinafoate 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] . therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, s

Amerika Serikat - Inggris - NLM (National Library of Medicine)

rebel distributors corp. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol xinafoate 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] .therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, su

Amerika Serikat - Inggris - NLM (National Library of Medicine)

physicians total care, inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol xinafoate 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] .therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, s

Amerika Serikat - Inggris - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - indacaterol maleate (unii: 2jec1itx7r) (indacaterol - unii:8or09251mq), glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - indacaterol 27.5 ug - utibrontm neohaler® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use: utibron neohaler is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.2)] . all labas are contraindicated in patients with asthma without use of a long-term asthma control medication [see warnings and precautions (5.1)] . utibron neohaler is not indicated for the treatment of asthma. utibron neohaler is contraindicated in patients who have demonstrated hypersensitivity to indacaterol, glycopyrrolate, or to any of the ingredients [see warnings and precautions (5.5)] . teratogenic effects: pregnancy category c there are no adequate and well-controlled studies with utibron neohaler or its individual components, indacaterol and glycopyrrolate, in pregnant women

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - mometasone furoate 200 ug - dulera is indicated for the twice-daily treatment of asthma in patients 12 years of age and older. dulera should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use: - dulera is not indicated for the relief of acute bronchospasm. dulera is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. dulera is contraindicated in patients with known hypersensitivity to mometasone furoate, formoterol fumarate, or any of the ingredients in dulera [see warnings and precautions (5.10)] . risk summary there are no randomized clinical studies of dulera, mometasone furoate, or formoterol fumarate in pregnant women. there are clinical considerations with the use of dulera in pregnant women [see clinical considerations] . animal

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol 50 ug - advair diskus is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. advair diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use advair diskus is not indicated for the relief of acute bronchospasm. advair diskus 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. advair diskus 250/50 is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. advair diskus 250/50 twice daily is the only approved dosage for the treatment of copd because an efficacy advantage of the higher strength advair diskus 500/50 over advair diskus 250/50 has not been demonstrated. important limitatio